cyc 682 has been researched along with tipifarnib in 2 studies
| Studies (cyc 682) | Trials (cyc 682) | Recent Studies (post-2010) (cyc 682) | Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) |
|---|---|---|---|---|---|
| 30 | 5 | 18 | 309 | 92 | 94 |
| Protein | Taxonomy | cyc 682 (IC50) | tipifarnib (IC50) |
|---|---|---|---|
| Chain B, Protein farnesyltransferase beta subunit | Rattus norvegicus (Norway rat) | 0.0007 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2.88 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Bos taurus (cattle) | 0.5503 | |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | 2.2237 | |
| Protein farnesyltransferase subunit beta | Bos taurus (cattle) | 0.0006 | |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | 0.0019 | |
| Geranylgeranyl transferase type-1 subunit beta | Homo sapiens (human) | 10 | |
| Geranylgeranyl transferase type-1 subunit beta | Bos taurus (cattle) | 1.1 | |
| Protein farnesyltransferase alpha subunit | Plasmodium falciparum (malaria parasite P. falciparum) | 0.017 | |
| CAAX farnesyltransferase subunit beta | Plasmodium falciparum (malaria parasite P. falciparum) | 0.017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baer, MR; Gojo, I | 1 |
| Burnett, AK; Hills, RK | 1 |
2 other study(ies) available for cyc 682 and tipifarnib
| Article | Year |
|---|---|
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom | 2011 |